Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Harun Fajkovic, Romain Mathieu, Ilaria Lucca, Manuela Hiess, Nicolai Hübner, Bashir Al Hussein Al Awamlh, Richard Lee, Alberto Briganti, Pierre Karakiewicz, Yair Lotan, Morgan Roupret, Michael Rink, Luis Kluth, Wolfgang Loidl, Christian Seitz, Tobias Klatte, Gero Kramer, Martin Susani, Shahrokh F. Shariat

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Objective: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort. Material and methods: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR. Results: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - Sep 14 2015

    Fingerprint

Keywords

  • Biochemical recurrence
  • Localized prostate cancer
  • Lymphovascular invasion
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Fajkovic, H., Mathieu, R., Lucca, I., Hiess, M., Hübner, N., Al Awamlh, B. A. H., Lee, R., Briganti, A., Karakiewicz, P., Lotan, Y., Roupret, M., Rink, M., Kluth, L., Loidl, W., Seitz, C., Klatte, T., Kramer, G., Susani, M., & Shariat, S. F. (Accepted/In press). Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2015.10.013